TX-MARY-KAY-INC
3.4.2024 20:13:34 CEST | Business Wire | Press release
Mary Kay Inc., a global leader in women’s empowerment and staunch advocate for sustainability, is once again at the forefront of global ocean conservation efforts. The beauty brand was proud to participate at the 11th Annual World Ocean Summit & Expo, held in Lisbon, Portugal, from March 11-13. As a bronze level sponsor for the second consecutive year, Mary Kay demonstrated its unwavering commitment to fostering a sustainable blue economy as a private sector representative and through its long-standing collaboration with The Nature Conservancy (TNC).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240403166440/en/
Sandra Silva, General Manager of Mary Kay in Portugal, shared insights on the crucial need for collaborative efforts in marine conservation and highlighted the impact of incorporating gender perspectives in initiatives tackling climate change challenges and biodiversity loss. (Photo: Mary Kay Inc.)
The Annual World Ocean Summit & Expo, organized by Economist Impact, convened over 200 expert speakers and a diverse international audience to engage in meaningful discussions, workshops, and "How to" sessions. These gatherings focused on actionable solutions to some of the most pressing oceanic challenges, underlining the importance of collaborative efforts across sectors.
Sandra Silva, General Manager of Mary Kay Portugal, took an active role in the panel discussion titled "Developing Blue Nature-based Projects." Silva shared insights on the crucial need for collaborative efforts in marine conservation and highlighted the impact of incorporating gender perspectives in initiatives tackling climate change challenges and biodiversity loss.
"Mary Kay's participation at this year's World Ocean Summit was not only about reinforcing our dedication to ocean conservation, but also about spotlighting the essential role of women in these efforts,” said Silva. “We believe that our collective actions today are pivotal for the preservation of marine ecosystems. All stakeholders left the summit with a clear vision on new synergies, a focus on actionable strategies, and soundproof solutions to enhance ocean stewardship.”
Dr. Lizzie Mcleod, Global Ocean Director for The Nature Conservancy, expressed gratitude for their long-term and impactful relationship with Mary Kay. "Our strong collaboration stands as a testament to the power of joining forces across the scientific community and the private sector to improve ocean health. Mary Kay’s support of marine conservation initiatives, including the Super Reefs project in Palau, is one example of our collective effort to ensure a healthy and resilient ocean."
Mary Kay has been working to elevate ocean health and coral reef awareness through its support of The Nature Conservancy for 37 years. Some of the most recent projects include the Super Reef restoration in the Asia Pacific region and other projects in Hawaii, Palau, the Marshall Islands, and Belize. These projects align with Mary Kay's mission to not only enrich lives but also to ensure the longevity and health of marine environments for future generations.
DID YOU KNOW?
- Mary Kay began supporting The Nature Conservancy (TNC) in 1987 and has now contributed to projects for more than three decades across 100 conservation projects around the globe.
- As part of its mission to conserve the Earth’s land and water, TNC aims to conserve 4 billion hectares of ocean by 2030—including coral reefs.
- Out of more than 1,500 articles published on coral reef sciences in OECD countries, 33% of authors were women.1
- 13-24% of senior positions in the EU’s marine sciences sector are occupied by women.1
- 90% of women in fisheries and aquaculture are more involved in less well-paid or unpaid work.1
About Mary Kay
Then. Now. Always. One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty brand in Texas in 1963 with one goal: to enrich women’s lives. That dream has blossomed into a global company with millions of independent sales force members in more than 35 countries. For 60 years, the Mary Kay opportunity has empowered women to define their own futures through education, mentorship, advocacy, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in preserving our planet for future generations, protecting women impacted by cancer and domestic abuse, and encouraging youth to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn, or follow us on X (formerly Twitter).
About The Nature Conservancy
The Nature Conservancy is a global conservation organization dedicated to conserving the lands and waters on which all life depends. Guided by science, we create innovative, on-the-ground solutions to our world’s toughest challenges so that nature and people can thrive together. We are tackling climate change, conserving lands, waters, and oceans at an unprecedented scale, providing food and water sustainably, and helping make cities more sustainable. Working in 76 countries and territories —37 by direct conservation impact and 39 through partners— we use a collaborative approach that engages local communities, governments, the private sector, and other partners. To learn more, visit www.nature.org or follow @nature_press on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240403166440/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
